A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects With Rheumatoid Arthritis
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 9
- 主要终点
- Incidence, nature, and severity of adverse events [Safety and Tolerability]
研究概览
简要总结
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown. Following completion of the initial single ascending dose cohorts, the study may evaluate alternative administration regimens of SBT777101, including split-dose administration. In the split-dose cohort, participants may receive two intravenous infusions of SBT777101 derived from a single manufacturing process, administered approximately 6 weeks apart. The study will continue to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.
详细描述
The study evaluates the safety and effects of a novel regulatory CARTreg cell-based autoimmune and inflammatory disease therapy for the treatment of rheumatoid arthritis. The therapy is an autologous (using the patient's own cells) Treg cell therapy that targets proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body mass index (BMI) <35 kg/m^2, inclusive
- •Adult-onset, moderate-to-severe rheumatoid arthritis (RA)
- •Moderate-to-severe active disease
- •b/tsDMARD failure criterion (≥2)
- •Swollen joint count ≥4
- •Clinical and/or ultrasound evidence of synovitis
- •Prior inadequate response to or unable to tolerate available RA therapies
- •Stable doses of RA medications for at least 30 days
- •Use of highly effective methods of contraception
排除标准
- •Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
- •Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
- •Recurrent infections or active infection
- •Active or untreated latent tuberculosis
- •Primary or secondary immunodeficiency
- •History of or current inflammatory joint disease other than RA
研究组 & 干预措施
SBT777101 Dose 3
High dose SBT777101
干预措施: SBT777101 (Biological)
SBT777101 Dose 2
Mid dose SBT777101
干预措施: SBT777101 (Biological)
SBT777101 Dose 1
Low dose SBT777101
干预措施: SBT777101 (Biological)
结局指标
主要结局
Incidence, nature, and severity of adverse events [Safety and Tolerability]
时间窗: Day of treatment to end of follow-up period (48 weeks)
Incidence and nature of dose-limiting toxicities (DLTs)
时间窗: Day of treatment to end of DLT evaluation period (28 days)
Death, CRS, ICANS, vital organ toxicity, hematological toxicity
次要结局
未报告次要终点